POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Trial details
- Registry ID
- NCT05953688
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUNCT05953688 | ALMS | Phase 2 | Terminated | 2024-08-13Actual |
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisNCT05600036 | ALMS | Phase 2 | Completed | 2023-06-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |